BioStock: Elicera’s CEO: ”2025 is a crucial year for us”

For Elicera, 2024 resulted in significant clinical progress and strategic initiatives that laid a solid foundation for continued development. The company entered 2025 with high ambitions, with data readouts from multiple clinical studies on the horison. BioStock contacted CEO Jamal el-Mosleh to get his perspective on the past year and what lies ahead. 

Read the interview at biostock.se:

https://www.biostock.se/en/2025/02/eliceras-ceo-2025-is-a-crucial-year-for-us/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/